« Return to News | CROs/Service Providers

MDS Pharma Services to Expand Early-Stage Operations in Taiwan

Thursday, June 11, 2009 07:50 AM

MDS Pharma Services, the CRO division of MDS, is undertaking a major renovation and expansion of its discovery operation in Taiwan as part of the company's recently announced plan to focus on early-stage clinical research.

MDS is doubling its capacity for in vivo safety and efficacy testing and improve its molecular screening and profiling capabilities at the Taiwan site. The project will be completed in 2010.

The Taiwan facility is part of MDS Pharma Services' Pharmacology/DMPK  service line, which offers molecular, cellular, ADME/DMPK and in vivo assays for drug development. The Taiwan site offers capabilities in molecular and cellular pharmacology, including more than 800 assays, multiple assay methodologies, high-throughput screening with robotic automation, and expert assay development.

"This new and expanded facility will cement our position as the global leader in the discovery pharmacology space, where we are one of the top two providers of molecular screening, and a key supplied of in vivo efficacy and safety testing," said MDS Pharma Services president David Spaight in a company statement.

MDS recently entered into deal with INC Research to sell off MDS Pharma's phase II through IV contract research business for $50 million. As part of that acquisition (expected to close in July), MDS announced that it would focus its Pharma Services unit on discovery through phase IIa proof-of-concept services.
 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.